ANI Pharmaceuticals Inc
NASDAQ:ANIP
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Price:
69.2
USD
-0.5%
Market Closed
Market Cap:
1.5B
USD
Balance Sheet
Balance Sheet Decomposition
ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc
| Current Assets | 527.7m |
| Cash & Short-Term Investments | 151.2m |
| Receivables | 221.7m |
| Other Current Assets | 154.8m |
| Non-Current Assets | 756m |
| PP&E | 56.9m |
| Intangibles | 601.8m |
| Other Non-Current Assets | 97.3m |
Balance Sheet
ANI Pharmaceuticals Inc
ANI Pharmaceuticals Inc
Currency: USD
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
155
|
27
|
31
|
43
|
62
|
8
|
100
|
48
|
221
|
145
|
|
| Cash Equivalents |
155
|
27
|
31
|
43
|
62
|
8
|
100
|
48
|
221
|
145
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
|
| Total Receivables |
23
|
46
|
60
|
65
|
73
|
96
|
132
|
169
|
162
|
222
|
|
| Accounts Receivables |
22
|
46
|
59
|
65
|
72
|
96
|
129
|
165
|
162
|
222
|
|
| Other Receivables |
1
|
0
|
1
|
0
|
1
|
0
|
4
|
4
|
0
|
0
|
|
| Inventory |
13
|
26
|
38
|
41
|
48
|
61
|
82
|
105
|
111
|
137
|
|
| Other Current Assets |
2
|
4
|
3
|
5
|
4
|
6
|
8
|
21
|
25
|
18
|
|
| Total Current Assets |
193
|
103
|
132
|
153
|
188
|
170
|
322
|
344
|
520
|
528
|
|
| PP&E Net |
7
|
11
|
20
|
38
|
41
|
41
|
53
|
43
|
45
|
57
|
|
| PP&E Gross |
7
|
11
|
20
|
38
|
41
|
41
|
53
|
43
|
45
|
57
|
|
| Accumulated Depreciation |
5
|
5
|
7
|
8
|
13
|
18
|
23
|
33
|
33
|
45
|
|
| Intangible Assets |
66
|
176
|
230
|
202
|
180
|
189
|
294
|
252
|
209
|
542
|
|
| Goodwill |
2
|
2
|
2
|
4
|
4
|
4
|
28
|
28
|
28
|
60
|
|
| Other Long-Term Assets |
17
|
31
|
29
|
35
|
45
|
58
|
75
|
93
|
103
|
97
|
|
| Other Assets |
2
|
2
|
2
|
4
|
4
|
4
|
28
|
28
|
28
|
60
|
|
| Total Assets |
285
N/A
|
323
+13%
|
412
+28%
|
431
+4%
|
457
+6%
|
461
+1%
|
772
+67%
|
760
-1%
|
904
+19%
|
1 284
+42%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
3
|
4
|
9
|
15
|
11
|
23
|
29
|
37
|
46
|
|
| Accrued Liabilities |
7
|
20
|
24
|
23
|
20
|
23
|
28
|
36
|
58
|
93
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
3
|
116
|
10
|
13
|
1
|
1
|
1
|
9
|
|
| Other Current Liabilities |
3
|
8
|
8
|
18
|
17
|
31
|
36
|
33
|
50
|
46
|
|
| Total Current Liabilities |
12
|
32
|
39
|
166
|
62
|
79
|
88
|
99
|
145
|
194
|
|
| Long-Term Debt |
113
|
121
|
198
|
67
|
176
|
172
|
287
|
286
|
285
|
615
|
|
| Other Liabilities |
0
|
1
|
0
|
1
|
7
|
15
|
39
|
36
|
17
|
46
|
|
| Total Liabilities |
125
N/A
|
153
+22%
|
237
+55%
|
233
-2%
|
244
+5%
|
266
+9%
|
413
+56%
|
422
+2%
|
447
+6%
|
855
+91%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
25
|
25
|
25
|
25
|
|
| Retained Earnings |
4
|
3
|
4
|
12
|
18
|
5
|
48
|
97
|
80
|
100
|
|
| Additional Paid In Capital |
164
|
173
|
179
|
187
|
201
|
214
|
388
|
404
|
514
|
520
|
|
| Treasury Stock |
0
|
0
|
0
|
1
|
1
|
2
|
3
|
5
|
10
|
21
|
|
| Other Equity |
0
|
0
|
0
|
0
|
5
|
11
|
3
|
12
|
9
|
5
|
|
| Total Equity |
160
N/A
|
170
+6%
|
175
+3%
|
197
+13%
|
213
+8%
|
196
-8%
|
359
+83%
|
339
-6%
|
458
+35%
|
429
-6%
|
|
| Total Liabilities & Equity |
285
N/A
|
323
+13%
|
412
+28%
|
431
+4%
|
457
+6%
|
461
+1%
|
772
+67%
|
760
-1%
|
904
+19%
|
1 284
+42%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
12
|
12
|
12
|
12
|
12
|
12
|
17
|
18
|
20
|
21
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
